Rheumatoid Arthritis Trial, Recruiting NCT06758817 Sponsor: Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Rheumatoid Arthritis Trial, Recruiting

NCT06758817
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with rheumatoid arthritis (RA) based on recognised medical guidelines
  • You are over 18 years old
  • You have had rheumatoid arthritis for more than 1 year
  • Your rheumatoid arthritis is currently active, meaning it is not well controlled (confirm with trial site)
  • You have been on the same arthritis medications without changes for at least 12 weeks
  • You currently have a low or medium level of adherence to a Mediterranean-style diet, based on a specific score (confirm with trial site)
  • You are willing and able to follow the study plan and requirements

Who may not be able to join:

  • You are taking prednisolone (a steroid) at a dose of 7.5 mg per day or more
  • You have taken antibiotics in the 4 weeks before the study start date
  • You regularly and continuously use anti-inflammatory painkillers (such as ibuprofen or naproxen)
  • You have inflammatory bowel disease or irritable bowel syndrome
  • You have coeliac disease (a reaction to gluten)
  • You have long-term or persistent diarrhoea
  • You have diabetes
  • You have another immune system or inflammatory disease in addition to rheumatoid arthritis
  • You have serious problems with a major organ (such as the heart, liver, or kidneys)
  • You have been diagnosed with cancer in the last five years
  • You have a cognitive (memory or thinking) impairment or psychiatric condition that may make participation difficult
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Catarina Sousa Guerreiro, RD PhD, Nutrition Lab, Faculty of Medicine, University of Lisbon

Phone: +351 217 999 474

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa
Registry
ClinicalTrials.gov
Start date
2 January 2023
Est. completion
30 September 2025

Where this trial is recruiting

🇵🇹 Portugal

Primary endpoints

DAS28-ESR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov